Safety biomarkers for drug-induced liver injury-current status and future perspectives

Toxicology Research

Volumn 3, Issue 2, 2014, Pages 75-85

  Antoine, Daniel J ^a   Harrill, Alison H ^b   Watkins, Paul B ^c,d   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CYTOKERATIN 18; GLUTAMATE DEHYDROGENASE; HIGH MOBILITY GROUP B1 PROTEIN; MICRORNA 122;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CIRCADIAN RHYTHM; CLINICAL ASSESSMENT; DISEASE PREDISPOSITION; DRUG TOXICITY; GENDER; GENOTYPE; HUMAN; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW; SAFETY; TARGET ORGAN; TOXIC HEPATITIS; XENOBIOTIC METABOLISM;

EID: 84894117898     PISSN: 2045452X     EISSN: 20454538     Source Type: Journal    
DOI: 10.1039/c3tx50077b     Document Type: Review

References (83)

1. W. M. Lee Drug-induced hepatotoxicity N. Engl. J. Med. 2003 349 5 474 485 (Pubitemid 36910027)
2. C. Sgro et al., Incidence of drug-induced hepatic injuries: a French population-based study Hepatology 2002 36 2 451 455 (Pubitemid 34810366)
3. Y. Meier et al., Incidence of drug-induced liver injury in medical inpatients Eur. J. Clin. Pharmacol. 2005 61 2 135 143 (Pubitemid 40674746)
4. A. Corsini et al., Current challenges and controversies in drug-induced liver injury Drug Saf. 2012 35 12 1099 1117
5. J. Moggs et al., Investigative safety science as a competitive advantage for Pharma Expert Opin. Drug Metab. Toxicol. 2012 8 9 1071 1082
6. D. J. Antoine et al., Mechanism-based bioanalysis and biomarkers for hepatic chemical stress Xenobiotica 2009 39 8 565 577
7. H. Olson et al., Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 2000 32 1 56 67
8. G. P. Aithal M. D. Rawlins C. P. Day Accuracy of hepatic adverse drug reaction reporting in one English health region BMJ 1999 319 7224 1541
9. G. Working Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin. Pharmacol. Ther. 2001 69 3 89 95
10. M. Ratner FDA pharmacogenomics guidance sends clear message to industry Nat. Rev. Drug Discovery 2005 4 5 359 (Pubitemid 40704100)
11. K. Matheis et al., A generic operational strategy to qualify translational safety biomarkers Drug Discovery Today 2011 16 13-14 600 608
12. P. B. Watkins Drug safety sciences and the bottleneck in drug development Clin. Pharmacol. Ther. 2011 89 6 788 790
13. B. K. Park et al., The role of metabolic activation in drug-induced hepatotoxicity Annu. Rev. Pharmacol. Toxicol. 2005 45 177 202 (Pubitemid 40261802)
14. B. K. Park et al., Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity Chem.-Biol. Interact. 2011 192 1-2 30 36
15. H. E. S. NHS, http://www.hesonline.nhs.uk/Ease/servlet/ContentServer? siteID=1937, 2011
16. W. M. Lee et al., Acute liver failure: Summary of a workshop Hepatology 2008 47 4 1401 1415 (Pubitemid 351547926)
17. C. D. Williams H. Jaeschke Role of innate and adaptive immunity during drug-induced liver injury Toxicol. Res. 2012 1 161 170
18. N. Kaplowitz Idiosyncratic drug hepatotoxicity Nat. Rev. Drug Discovery 2005 4 6 489 499 (Pubitemid 40861991)
19. J. R. Mitchell et al., Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism J. Pharmacol. Exp. Ther. 1973 187 1 185 194
20. J. R. Mitchell et al., Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione J. Pharmacol. Exp. Ther. 1973 187 1 211 217
21. D. J. Jollow et al., Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo J. Pharmacol. Exp. Ther. 1973 187 1 195 202
22. W. Z. Potter et al., Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro J. Pharmacol. Exp. Ther. 1973 187 1 203 210
23. D. J. Antoine et al., Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital Hepatology 2013 58 2 777 787
24. J. W. Dear et al., Letter to the Editor: Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis Br. J. Clin. Pharmacol. 2013 10.1111/bcp.12214
25. R. E. Ferner J. W. Dear D. N. Bateman Management of paracetamol poisoning BMJ 2011 342 d2218
26. J. Ozer et al., The current state of serum biomarkers of hepatotoxicity Toxicology 2008 245 3 194 205
27. P. B. Watkins et al., Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease JAMA 1994 271 13 992 998 (Pubitemid 24099919)
28. A. H. Harrill et al., The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers Clin. Pharmacol. Ther. 2012 92 2 214 220
29. J. R. Senior Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future Clin. Pharmacol. Ther. 2012 92 3 332 339
30. P. B. Watkins et al., Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery Drug Saf. 2011 34 3 243 252
31. G. P. Aithal et al., Case definition and phenotype standardization in drug-induced liver injury Clin. Pharmacol. Ther. 2011 89 6 806 815
32. X. Zhang et al., Involvement of the immune system in idiosyncratic drug reactions Drug Metab. Pharmacokinet. 2011 26 1 47 59
33. M. Coen A metabonomic approach for mechanistic exploration of pre-clinical toxicology Toxicology 2010 278 3 326 340
34. A. Van Summeren et al., Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity Toxicol. In Vitro 2012 26 3 373 385
35. L. N. Bell et al., Serum proteomic profiling in patients with drug-induced liver injury Aliment. Pharmacol. Ther. 2012 35 5 600 612
36. J. V. Bonventre et al., Next-generation biomarkers for detecting kidney toxicity Nat. Biotechnol. 2010 28 5 436 440
37. V. S. Vaidya et al., Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies Nat. Biotechnol. 2010 28 5 478 485
38. B. F. Feldman, Cerebrospinal Fluid, in Clinical Biochemistry of Domestic Animals, ed., J. Kaneko, Academic Press, San Diego, 1989, pp. 835-865
39. M. D. Stonard, Assessment of Nephrotoxicity, in Animal Clinical Chemistry, ed., G. O. Evans, Taylor & Francis, London, 1996, pp. 87-89
40. E. S. Schmidt F. W. Schmidt Glutamate dehydrogenase: biochemical and clinical aspects of an interesting enzyme Clin. Chim. Acta 1988 173 1 43 55
41. S. Schomaker et al., Assessment of emerging biomarkers of liver injury in human subjects Toxicol. Sci. 2013 132 2 276 283
42. P. J. O'Brien et al., Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats Lab. Anim. 2002 36 3 313 321 (Pubitemid 34785766)
43. M. R. McGill et al., The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation J. Clin. Invest. 2012 122 4 1574 1583
44. R. Singhal et al., Mechanistic biomarkers of liver safety and benign elevations in serum aminotransferases-A study in healthy volunteer treated with cholestyramine Br. J. Clin. Pharmacol. 2013
45. P. Scaffidi T. Misteli M. E. Bianchi Release of chromatin protein HMGB1 by necrotic cells triggers inflammation Nature 2002 418 6894 191 195 (Pubitemid 34773774)
46. H. Wang et al., HMG-1 as a late mediator of endotoxin lethality in mice Science 1999 285 5425 248 251 (Pubitemid 29329996)
47. H. Yang et al., The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis J. Leukocyte Biol. 2013 93 6 865 873
48. S. Nystrom et al., TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis EMBO J. 2013 32 1 86 99
49. B. Lu et al., Novel role of PKR in inflammasome activation and HMGB1 release Nature 2012 488 7413 670 674
50. H. Yang et al., Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1) Mol. Med. 2012 18 1 250 259
51. E. Venereau et al., Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release J. Exp. Med. 2012 209 9 1519 1528
52. D. J. Antoine et al., High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo Toxicol. Sci. 2009 112 2 521 531
53. D. G. Craig et al., Circulating apoptotic and necrotic cell death markers in patients with acute liver injury Liver Int. 2011 31 8 1127 1136
54. D. J. Antoine et al., Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity J. Hepatol. 2012 56 5 1070 1079
55. N. O. Ku et al., Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies Hepatology 2007 46 5 1639 1649
56. C. Caulin G. S. Salvesen R. G. Oshima Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis J. Cell Biol. 1997 138 6 1379 1394 (Pubitemid 27415063)
57. B. Schutte et al., Keratin 8/18 breakdown and reorganization during apoptosis Exp. Cell Res. 2004 297 1 11 26 (Pubitemid 38759558)
58. A. Wieckowska et al., In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease Hepatology 2006 44 1 27 33 (Pubitemid 44049136)
59. J. Cummings et al., Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity Mol. Cancer Ther. 2008 7 3 455 463 (Pubitemid 351482128)
60. N. O. Ku et al., Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant J. Clin. Invest. 1996 98 4 1034 1046
61. P. Strnad et al., Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations Gastroenterology 2010 139 3 828 835
62. L. P. Bechmann et al., Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury J. Hepatol. 2010 53 4 639 647
63. P. J. Starkey Lewis et al., Serum microRNA biomarkers for drug-induced liver injury Clin. Pharmacol. Ther. 2012 92 3 291 293
64. K. Zen C. Y. Zhang Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers Med. Res. Rev. 2012 32 2 326 348
65. K. Wang et al., Circulating microRNAs, potential biomarkers for drug-induced liver injury Proc. Natl. Acad. Sci. U. S. A. 2009 106 11 4402 4407
66. Y. Zhang et al., Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases Clin. Chem. 2010 56 12 1830 1838
67. P. J. Starkey Lewis et al., Circulating microRNAs as potential markers of human drug-induced liver injury Hepatology 2011 54 5 1767 1776
68. J. W. Sharkey D. J. Antoine B. K. Park Validation of the isolation and quantification of kidney enriched miRNAs for use as biomarkers Biomarkers 2012 17 3 231 239
69. M. Chen et al., FDA-approved drug labeling for the study of drug-induced liver injury Drug Discovery Today 2011 16 15-16 697 703
70. R. J. Fontana et al., Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop Hepatology 2010 52 2 730 742
71. T. J. Urban et al., Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs Pharmacogenet. Genomics 2012 22 11 784 795
72. S. Mallal et al., HLA-B*5701 screening for hypersensitivity to abacavir N. Engl. J. Med. 2008 358 6 568 579
73. A. Alfirevic et al., Explanation for HLA-B*57:01-linked immune-mediated abacavir-induced hypersensitivity Pharmacogenomics 2012 13 14 1567 1569
74. A. K. Daly et al., HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat. Genet. 2009 41 7 816 819
75. M. I. Lucena et al., Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles Gastroenterology 2011 141 1 338 347
76. Y. Cai et al., Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis PLoS One [Electronic Resource] 2012 7 10 e47769
77. N. Chalasani E. Bjornsson Risk factors for idiosyncratic drug-induced liver injury Gastroenterology 2010 138 7 2246 2259
78. A. K. Daly et al., Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes Gastroenterology 2007 132 1 272 281 (Pubitemid 46108755)
79. C. Lang et al., Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury Pharmacogenet. Genomics 2007 17 1 47 60 (Pubitemid 46183791)
80. J. Noe et al., Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis J. Hepatol. 2005 43 3 536 543 (Pubitemid 41111438)
81. A. H. Harrill et al., Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans Genome Res. 2009 19 9 1507 1515
82. A. H. Harrill et al., A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models Toxicol. Sci. 2012 130 2 416 426
83. D. J. Antoine et al., Are we closer to finding biomarkers for identifying acute drug-induced liver injury? Biomark Med. 2013 7 3 383 386